STGenBio Showcases Global CMO Capabilities

[Financial News] STGenBio is enhancing its global pharmaceutical contract manufacturing (CMO) capabilities. STGenBio is focusing on the biopharmaceutical CMO business of the Dong-A Socio Group. It is expanding its scope, starting with the production of the biosimilar 'Imuldosa' developed by Dong-A ST.
According to the pharmaceutical industry on the 22nd, STGenBio's capabilities are being highlighted again as it secured a total of 14 billion KRW worth of contracts with domestic and global pharmaceutical companies last June and July.
A representative from STGenBio said, “In the past, we focused on proving quality, but now the key is to respond to demand and large-scale production capabilities,” adding, “The scale of single contracts is changing.”
STGenBio is actively working to secure more clients. In June, it participated in BioUSA, known as the largest conference in the global bio field, and met potential clients.
In July, it set up a solo booth at INTERPHEX Tokyo for the third consecutive year to introduce its production infrastructure. It is known that over 100 business meetings were held at the two events.
STGenBio is also preparing strategies to attract more clients. The production facility, considered its greatest strength, can currently produce 28 million pre-filled syringes (PFS) annually. To improve response capabilities, it plans to expand the cultivation line and harvest line and is considering establishing a second plant.
To further enhance quality, it will introduce new aseptic filling equipment. The company aims to leverage its high quality, which has allowed it to pass inspections by global regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) simultaneously.
A representative from STGenBio emphasized, "We have established a production system based on advanced quality standards. We are changing to enable competitive orders from more clients," adding, "We will strive to become a global CMO company."

vrdw88@fnnews.com Kang Jung-mo Reporter